British Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed using technology, which was licenced from Abzenawhich was licenced from Abzena.
Addex further improves liquidity
Latest NewsFollowing a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.
Gyros Protein Technologies: European Marketing
AppointmentsGyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.
Improved automated Liquid Handling performance
ProductsEppendorf extends its range of accessories and consumables for the epMotion® 5070, 5053 and 5075 automated Liquid Handling systems to facilitate pipetting of small volumes from 10 µL down to 200 nL.
AMO Pharma receives FDA Fast Track Status
Latest NewsLondon-based orphan drug developer AMO Pharma’s drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy.
Biocorp partners with Virbac
Latest NewsFrench drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers.
GenSight Biologics: Progressing the ophthalmic pipeline
AppointmentsParis-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.
Janssen speeds up guselkumab approval process
Latest NewsJanssen speeds up US approval of psoriasis antibody guselkumab and targets further indications.
Abzena’s partner True North Therapeutics subject of US$825m take-over
Latest NewsBritish Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed using technology, which was licenced from Abzenawhich was licenced from Abzena.
RA: Sanofi/Regeneron IL-6R blocker FDA-approved
Latest NewsFollowing the EMA’s recommendation for EU approval of sarilumab as second-line treatment for rheumatoid arthritis, French drug giant Sanofi and partner Regeneron have also been given the green light from the US FDA.
Safety event delays US market approval of romosozumab
Latest NewsTop-Line Phase 3 data of Amgen’s/UCB’s osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal.